Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: A single-center experience

Peng Liu,Xin Wang,Huan Liu,Shu-Xian Wang,Qing-Guo Xu,Lin Wang,Xiao Xu,Jin-Zhen Cai

DOI: https://doi.org/10.1016/j.hbpd.2022.11.010

2022-12-03

Abstract:Background Tumor recurrence after liver transplantation (LT) for selective patients diagnosed with hepatocellular carcinoma (HCC) in the setting of cirrhosis is the greatest challenge effecting the prognosis of these patients. The aim of this study was to evaluate the efficacy of sirolimus on the prognosis for these recipients. Methods The data from 193 consecutive patients with HCC who had undergone LT from January 2015 to December 2019 were retrospectively analyzed. These patients were divided into the sirolimus group [patients took sirolimus combined with calcineurin inhibitors (CNIs) ( n = 125)] and non-sirolimus group [patients took CNI-based therapy without sirolimus ( n = 68)]. Recurrence-free survival (RFS) and overall survival (OS) were compared between the two groups. The prognostic factors and independent risk factors for RFS and OS were further evaluated. Results Non-sirolimus was an independent risk factor for RFS (HR = 2.990; 95% CI: 1.050-8.470; P = 0.040) and OS (HR = 3.100; 95% CI: 1.190-8.000; P = 0.020). A higher proportion of patients beyond Hangzhou criteria was divided into the sirolimus group (69.6% vs. 80.9%, P = 0.030). Compared with the non-sirolimus group, the sirolimus group had significantly better RFS ( P < 0.001) and OS ( P < 0.001). Further subgroup analysis showed similar results. Conclusions This study demonstrated that sirolimus significantly decreased HCC recurrence and prolonged RFS and OS in LT patients with different stage of HCC.

gastroenterology & hepatology